Search results
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 5 days agoThe crackdown is the latest assault against what the agency regards as drugmakers’ patent ploys...
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
Bloomberg Law· 6 days agoOzempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved ...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 6 days agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
The Misunderstood World of Medication Pricing
The Motley Fool· 3 days agoIf you happen to be one of the 131 million Americans who take doctor-prescribed medications, you probably already know that drug prices can feel...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 5 days agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...
White House Aims to Reclassify Marijuana as Less Dangerous Drug - What’s News - WSJ Podcasts
The Wall Street Journal· 5 days agoAnnmarie Fertoli: The Biden administration wants to reclassify marijuana as a less dangerous drug....
FTC cracks down on drugmaker patents, including Novo's Ozempic; analysts weigh in By Investing.com
Investing.com· 6 days agoTrade Commission (FTC) said it is challenging hundreds of what it calls "junk" patents associated...
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Zacks via Yahoo Finance· 4 days agoNovo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and...
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Yahoo Finance· 4 days agoTrade Commission recently sent a warning letter to 10 companies, including Novo Nordisk, concerning...
Novo Nordisk: Growth Is Still A Better Choice
GuruFocus.com via Yahoo Finance· 7 days agoIts sales were about 30 billion krone in the fourth quarter of 2023, up 77.10% year over year due to an increase in its share of the global type 2...
